Biocer

What Biocer does

BioCer Entwicklungs-GmbH is a privately held German medical technology company headquartered in Bayreuth, founded in 1998 as a spin-off from the University of Bayreuth and commercially active since 2010. The company develops and manufactures medical devices across three product pillars: haemostatic agents under the HaemoCer brand (plant-based polysaccharide powders plus a growing family of applicators including Universal, Flex, and Endoscopic variants and bundled sets); titanium-dioxide-coated surgical meshes under the TiO2Mesh brand for hernia and breast reconstruction; and functional implant surface coatings (TiOCer for anti-allergenic barrier, OsteoCer for osteoconductive bone ingrowth, and SeptoCer for antibacterial protection). Underlying technology rests on proprietary sol-gel ceramic coating processes and the PURE (Polysaccharide Ultra-hydrophilic Resorbable Engineering) polysaccharide platform, with all products designed to contain no animal or human components and manufactured in ISO 13485 / EU MDR 2017/745-compliant clean room facilities.

BioCer generates revenue through hardware sales of these CE-marked medical devices, distributed via a worldwide distributor network reaching approximately 80 countries, supported by an internal sales team for logistics and field sales representatives for distributor training and local hospital engagement. The go-to-market is primarily channel-partner-led, complemented by trade fair participation across Europe, Asia, and the Americas (UEG Week, Medica, ESGE Days, EACTS, EHS, etc.) and standard digital channels (LinkedIn, YouTube, website). End customers span multiple surgical disciplines—general surgery, hernia, endoscopy, ENT, cardiovascular, thoracic, orthopedics, traumatology, breast reconstruction—with quote-based B2B pricing to hospitals and surgical centers. The company holds no disclosed institutional investment, has no funding rounds on record, and operates as a bootstrapped privately held GmbH with two managing directors (Frank Heidenau and Dr. Markus Heinlein) and a headcount in the 11–50 range.

Name

Biocer

Legal name

BioCer Entwicklungs-GmbH

Website

https://biocer-gmbh.de

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

BioCer Entwicklungs-GmbH is a German medical technology company that develops and manufactures animal-component-free haemostatic powders, titanium-coated surgical meshes, and functional implant coatings, sold through a global distributor network to hospitals in approximately 80 countries.

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM)

Keywords

• Hemostatic agents
• Surgical mesh implants
• Implant surface coatings
• Medical device manufacturing
• Biomaterial medical products

Headquarters

HQ city

Bayreuth

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Products: BioCer generates revenue through the development, production, and sale of medical devices including haemostatic agents (HaemoCer powder and applicators), surgical mesh implants (TiO2Mesh product lines), and functional coatings for implant surfaces. Products are sold through a worldwide distributor network to hospitals and medical practices globally.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

BioCer Entwicklungs-GmbH researches, develops, manufactures and distributes plant-based, animal- and human-component-free medical devices. The portfolio spans three lines: plant-based haemostatic agents (HaemoCer and HaemoCer PLUS) for surgical bleeding control; titanium dioxide-coated surgical mesh implants (TiO2Mesh family) for hernia repair and breast reconstruction; and functional implant surface coatings (TiOCer anti-allergenic, OsteoCer bone-growth-promoting, SeptoCer antibacterial). All products are manufactured in clean rooms in Bayreuth, Germany under DIN EN ISO 13485 and EU MDR 2017/745.

Product overview

BioCer Entwicklungs-GmbH is a medical technology company specializing in research, development, and production of innovative medical devices from biomaterials without animal or human components. The product portfolio consists of three main categories: (1) Haemostasis products centered on the HaemoCer brand, including HaemoCer powder, HaemoCer PLUS with adhesion prevention capability, and various applicator systems (Universal Applicator, FlexApplicator, Endoscopic Applicator) and bundled sets for different surgical applications; (2) Surgical Mesh implants under the TiO2Mesh brand, offering standard and lightweight versions for hernia surgery, plus TiO2Mesh BRA variants for breast reconstruction; (3) Functional Coating technologies including SeptoCer (antibacterial), OsteoCer (bone growth-promoting), and TiOCer (anti-allergenic) coatings for implant surface modification. All products are developed and manufactured in Germany (Bayreuth) following DIN EN ISO 13485 and EU MDR 2017/745 standards.

Differentiator

Problem solved

Functional benefit

Brands

• HaemoCer: Herbal powdered hemostatic agent for supportive haemostasis and adhesion prevention during surgical procedures
• TiO2Mesh
• SeptoCer
• OsteoCer
• TiOCer

Products and services

• HaemoCer Herbal powdered haemostatic agent (100% purified plant-based starch) for supportive haemostasis during surgical procedures, containing no animal or human components; sold to hospitals and surgical centers.
• HaemoCer PLUS Advanced plant-based haemostatic powder with dual functionality for supportive haemostasis and adhesion prevention during surgical procedures, developed using PURE Technology (Polysaccharide Ultra-hydrophilic Resorbable Engineering) and fully resorbed by the body via amylase.
• HaemoCer Universal Applicator Standalone delivery instrument for applying HaemoCer powder in laparoscopic, ENT, spinal and other minimally invasive surgical procedures, with integrated shut-off clamp and moisture-resistant applicator tip.
• HaemoCer FlexApplicator Flexible standalone applicator with integrated wire for moulding and dimensional stability, used to apply HaemoCer powder at blind spots and complex challenging surgical sites.
• HaemoCer Endoscopic Applicator Standalone 2400 mm applicator with 2.5 mm outer diameter and built-in HEPA filter for haemostasis during upper and lower gastrointestinal tract endoscopies, requiring no external aids.
• TiO2Mesh Large-pored (2.8 mm), lightweight (47 g/m²) hernia mesh implant with biocompatible titanium dioxide coating, laser-cut edges and self-fixing hydrophilic surface for tissue reinforcement during hernia surgery.
• TiO2Mesh light Lighter version (32 g/m² basis weight, 50 N/cm tensile strength) of the TiO2Mesh hernia implant with titanium dioxide coating, intended for inguinal, umbilical, femoral and incisional hernias.
• TiO2Mesh BRA Titanium-dioxide-coated surgical mesh implant (47 g/m²) for support and reinforcement of soft tissue in reconstructive and plastic-aesthetic breast surgery.
• TiO2Mesh BRA light Lightweight (32 g/m²) version of TiO2Mesh BRA for soft tissue reinforcement in breast surgery with optimized handling properties.
• SeptoCer Antibacterial implant coating based on thin titanium oxide functionalized with metal ions, providing controlled-release antibacterial effect to reduce biofilm formation and risk of late implant loosening, with metal-ion concentrations far below cytotoxic levels.
• OsteoCer Bone growth-promoting (osteoconductive) inorganic coating with incorporated calcium ions, suitable for ceramic implant materials and orthopedic alloys; adhesion strength exceeds 100 N/mm² via direct chemical bonding, and it is compatible with all sterilization methods.
• TiOCer Anti-allergenic ceramic-like titanium oxide implant coating that reduces leaching of nickel, cobalt and chrome ions from implant surfaces, with direct chemical bonding to alloy surfaces and thermal treatment that preserves mechanical properties and shelf life.

Quantifiable outcome

• TiO2Mesh light: 32 g/m² basis weight with 50 N/cm tensile strength; Standard TiO2Mesh: 47 g/m² with 55 N/cm tensile strength; pore size 2.8 mm for both variants
• +2 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Hernia mesh portfolio (Symbotex, Versatex, Parietex) competes with TiO2Mesh in the same surgical channels; broader portfolio provides incumbency advantages in hospital purchasing.
• Ethicon (Johnson & Johnson MedTech): Largest surgical mesh franchise (Prolene, Physiomesh, Proceed) and haemostat portfolio (Surgicel, Surgiflo); competes with BioCer across both core product categories in general surgery and hernia repair.
• Becton Dickinson (BD): Surgical mesh portfolio (Phasix, Ventralight) and Arista AH absorbable hemostat directly overlap with BioCer's TiO2Mesh and HaemoCer product lines; serves the same surgical specialties.
• Getinge (Atrium/Maquet mesh): Herniamesh portfolio and broader surgical specialties business competes with BioCer's TiO2Mesh in hernia repair and soft tissue reinforcement markets, with established hospital relationships.
• Baxter International: Global medical device and pharmaceutical company; its haemostasis portfolio (FloSeal, Tisseel) competes directly with BioCer's HaemoCer in surgical bleeding control across the same hospital surgical departments.
• B. Braun: Optilene surgical mesh and broader surgical supplies portfolio directly compete with BioCer's TiO2Mesh in European hospital channels, with comparable regulatory depth and larger sales infrastructure.
• Pfizer (Hospital business / Gelfoam): Gelfoam absorbable gelatin hemostat is a legacy competitor in surgical haemostasis; competes with HaemoCer in procedures where animal-derived gelatin is acceptable, particularly in price-sensitive accounts.

Emerging players

• LifeBond (LifeMesh, LifeSeal): Israel-based company with proprietary bioadhesive and surgical mesh/sealant technology; overlaps with BioCer in surgical sealing and mesh innovation, though with different chemistry (bioactive polymers vs. TiO2 coating).

Direct peers

• aap Implantate: German-headquartered orthopedics and trauma implant company with antibacterial coating technology (silver-coated implants); competes with BioCer's SeptoCer/OsteoCer in functionalized implant surface technologies.
• Starch Medical (subsidiary of Hangzhou Singclean): Direct competitor in plant-derived polysaccharide hemostats with comparable technology positioning; serves the same surgical haemostasis market with similar 'animal-free' value proposition, particularly in Asia and emerging markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCxr_AVCDv9GaW4qDmYNPezg
• Facebookfacebook.com/biocergmbh
• LinkedInlinkedin.com/company/biocer-entwicklungs-gmbh
• Instagraminstagram.com/biocer_gmbh

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocer